Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny study hopes to unlock why pollution hurts some lungs more

NCT ID NCT02743468

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 17, 2026 · Updated 12 times

Summary

This completed study looked at how genetic differences might change the way immune cells in the lungs respond to environmental triggers like dust and germs. Researchers collected blood and lung samples from 20 healthy adults to compare cell function between people with different gene variants. The goal was to better understand why some people develop lung inflammation, not to test a new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain why some people are more prone to lung inflammation from pollution, pointing toward future prevention strategies.
What could go wrong
This is a very small, early-stage observational study (20 people) that does not test any treatment. It may not lead to direct health benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Jan 2019

Finished

Sep 2023

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: 1. Age 18 to 65 years, inclusive (males and females) 2. Able to travel to the NIEHS CRU for required study visits 3. Able to present a valid government-issued form of identification for entry to the NIEHS campus 4. Able to fast for 8 hours prior to the visit where bronchoscopy occurs 5. Has a responsible party who is willing and able to attend Visit 2 and drive the participant away from the CRU after completion of Visit 2, if the participant elects to undergo conscious sedation 6. Genotype information available for relevant CYP2J2 and EPHX2 polymorphisms, which indicates: * Wild type with respect to EPHX2 K55R, EPHX2 R287Q, and CYP2J2\*7; or * Homozygous for EPHX2 K55R (wild type for the other SNPs); or * Homozygous for EPHX2 R287Q (wild type for the other SNPs); or * Homozygous for CYP2J2\*7 (wild type for the other SNPs) EXCLUSION CRITERIA: 1. Current pregnancy or lactation, as medications used during the bronchoscopy can be excreted in the breast milk of lactating mothers 2. Current smoker or significant second-hand smoke exposure (defined by urine cotinine \>200 ng/mL at screening) 3. Post-bronchodilator FEV1 \< 70% of predicted 4. For asthmatics, any indication of moderate or severe asthma such as: * Physician-directed emergency treatment for an asthma exacerbation within the preceding 12 months * Any use of systemic steroid therapy during the last year or continuous use of inhaled steroids over a period of 1 month or longer during the past 6 months * Regular use of cromolyn (except for prophylaxis of exercise induced bronchospasm) or any use of leukotriene inhibitors (Montelukast or Zafirlukast) within the past month * Symptoms including: * Night-time symptoms of cough or wheeze greater than 1x/week * Exacerbations of asthma more than 2x/week * Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) 5. Bleeding disorders or regular use of aspirin or other non-steroidal anti-inflammatory drugs (which inhibit platelet function) or other drugs that prolong bleeding time such as warfarin, heparin or derivatives, or clopidogrel and related ADP inhibitors 6. Sickle cell disease or GP6 deficiency 7. Facial deformity or major facial surgery 8. Asthma exacerbation or respiratory infection 4 weeks prior to study visit 9. Allergy or history of adverse reactions to lidocaine, midazolam, or fentanyl 10. Vital signs (temperature, blood pressure, pulse rate) that are outside of the established CRU limits 11. Body weight \<50 kg (\<110 lbs) 12. The following abnormal clinical laboratory values (obtained during Visit 1 assessment): * Platelet count \<100,000 per L * White blood cells count \<3000 per L * Absolute neutrophil count \<1000 per L * Hematocrit \<35% for both female and male * PT/INR and PTT based on reference laboratory established reference ranges * Serum creatinine \>1.4 mg/dL 13. Any condition that, in the investigator's opinion, places the participant at undue risk for complications associated with required study procedures. 14. Use of the medication colchicine (commonly used to treat gout attacks) in the past 2 weeks. Volunteers meeting any of the below temporary exclusions may enroll in the study, but may not undergo the bronchoscopy procedure within the time frames specified for each below temporary exclusion. If any of the following conditions are met, the bronchoscopy will be rescheduled such that none of these temporary exclusions apply: Temp. EXCL 1. An asthma exacerbation requiring increased asthma medications for more than 1 day (and other than exercise-induced asthma) within 1 month of bronchoscopy Temp. EXCL 2. Viral upper respiratory tract infection or any acute infection requiring antibiotics within 4 weeks of bronchoscopy Temp. EXCL 3. Use of anti-inflammatory medications (including over-the-counter preparations) during the 48 hours prior to the bronchoscopy and aspirin during the 14 days prior to bronchoscopy. Temp. EXCL 4. Any food or fluids for 8 hours prior to the bronchoscopy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NIEHS, Research Triangle Park

    Research Triangle Park, North Carolina, 27709, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.